 |
 |
- AOP Health and LBI-NetMed combine expertise in rare diseases, drug development and computational biology.
- The partnership aims to generate deeper insights into potential drug candidates and future therapeutic opportunities.
- The collaboration supports faster, evidence-based development of urgently needed therapies for people living with rare diseases.
VIENNA, Austria, November 05, 2026 / Biotech Newswire / -- The Austrian pharmaceutical company AOP Health and the Ludwig Boltzmann Institute for Network Medicine at the University of Vienna (LBI-NetMed) have launched a strategic scientific partnership to accelerate drug development. By combining AOP Health's expertise in rare diseases and pharmaceutical development with LBI-NetMed's capabilities in computational biology and network medicine, the partners aim to deepen the understanding of disease mechanisms. These insights can help identify promising therapeutic opportunities and support faster, evidence-based development decisions. The collaboration has already started with a joint pilot project and is designed as a long-term academic-industry partnership.
Increasingly, medicine is moving away from viewing diseases as the result of a single faulty gene or protein and towards understanding them as the consequence of complex interactions across entire biological systems. This network-based perspective is helping researchers uncover how disturbances across interconnected pathways drive disease and why understanding these interactions is essential for developing new therapies.
Translating Research into Application
To gain these insights, LBI-NetMed develops and applies advanced computational approaches that can map, visualize and analyze biological networks, with a particular focus on protein interactions.
To date, these approaches have largely been used in basic research settings. The collaboration with AOP Health creates an opportunity to further advance these methods and translate them into drug-development and clinical research activities.
“This partnership enables us to bring our technology from research into practical application. Working with AOP Health allows us to demonstrate how our network-driven methodologies can support innovation and contribute to better outcomes for people living with rare diseases,” said Prof. Jörg Menche, Institute Director of LBI-NetMed at the University of Vienna.
Supporting Smarter Development Decisions
For AOP Health, the partnership opens new opportunities to integrate network-based approaches into drug development. The joint platform enables researchers to investigate how drug candidates influence biological networks while also supporting the identification and prioritization of promising therapeutic targets. By combining computational insights with pharmaceutical development expertise, the collaboration aims to strengthen decision-making throughout the development process.
“LBI-NetMed’s specialized expertise in computational biology and network science adds a valuable new dimension to our development capabilities. By helping us gain deeper insights into disease mechanisms and potential therapies, the partnership supports the identification of new indications, better- informed decision-making in development programs and has the potential to accelerate the delivery of urgently needed treatments for patients with rare diseases,” said Zoltan Magyarics, MD PhD, VP Research & Development, AOP Health.
Launching the Joint Pilot
The collaboration has already moved into active scientific work. The first joint pilot project focuses on one of AOP Health's development assets and will explore how advanced computational approaches can complement existing drug development activities. Both organizations view the pilot as the first step in a longer-term collaboration aimed at turning scientific insights into practical value for patients.
For high resolution please click the image.
AI Semantic Keywords: Rare Diseases; Network Medicine; AOP Health; Ludwig Boltzmann Institute for Network Medicine (LBI-NetMed); University of Vienna; Network Data Science; Network-Based Approaches; Computational Approaches; Joint Pilot Project; Academic-Industry Partnership; Long-Term Scientific Partnership; Pharmaceutical Development; Drug Development; Computational Biology; Disease Mechanisms; Therapeutic Opportunities; Therapeutic Targets Identification; Protein Networks; Biological Pathways; Interconnected Pathways; Drug Development Decisions; Academic-Industry Partnership; Evidence-Based Development; Zoltan Magyarics; Jörg Menche
About LBI-NetMed
The Ludwig Boltzmann Institute for Network Medicine at the University of Vienna (LBI-NetMed) is a computational, data-driven institute dedicated to establishing a network-based understanding of human health across biological scales and translating these insights into medical and societal impact.
About AOP Health
AOP Health Group is a global pharmaceutical health care group with headquarters in Vienna. Its mission is to address high unmet medical needs through impactful, science-driven therapies and care models. Since 1996, AOP Health has pioneered research where limited therapies exist, to develop solutions for patients with rare diseases and severe conditions in niche therapeutic areas. Guided by the principle "Needs. Science. Trust.” the AOP Health Group demonstrates its strong commitment to patients and healthcare professionals through innovation and long-term partnerships, to improve patient outcomes worldwide.
Contact
AOP Health
DI Isolde Fally
This email address is being protected from spambots. You need JavaScript enabled to view it.
+43-676-500 4048
https://www.aop-health.com
Source: Biotech Newswire